Mercado mundial de tratamiento de la migraña: tendencias de la industria y pronóstico hasta 2029

Personalice su informePersonalice su informe Compre ahoraCompre ahora Ejemplo de informe gratuitoEjemplo de informe gratuito
Hogar Healthcare Global Migraine Treatment Market
Solicitud de índiceSolicitud de índice Hable con el analistaHable con el analista Comprar ahoraComprar ahora Consultar antes de comprarConsultar antes Informe de muestra gratuitoInforme de muestra gratuito

Mercado mundial de tratamiento de la migraña: tendencias de la industria y pronóstico hasta 2029

  • Healthcare
  • Upcoming Report
  • May 2022
  • Global
  • 350 Páginas
  • Número de tablas: 220
  • Número de figuras: 60
Comprar ahoraComprar ahora

Global Migraine Treatment Market

Tamaño del mercado en miles de millones de dólares

Tasa de crecimiento anual compuesta (CAGR) :  % Diagram

Diagram Período de pronóstico
 2022 –2029
Diagram Tamaño del mercado (año base)
 USD 2.38 Billion
Diagram Tamaño del mercado (año de pronóstico)
 USD 4.67 Billion
Diagram Tasa de crecimiento anual compuesta (CAGR)
 %
Diagram Jugadoras de los principales mercados
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5
Solicitud de desbloqueo

>Mercado mundial de tratamiento de la migraña, por tipos (episódica, migraña con aura, crónica y otras), tratamiento (tratamiento agudo/abortivo, tratamiento preventivo/profiláctico, terapias y dispositivos no farmacológicos), vía de administración (oral, parenteral, aerosoles nasales y otros), tipo de producto (con receta y sin receta), tipo (de marca y genérico), usuario final (hospitales, clínicas, atención domiciliaria, otros), canal de distribución (farmacias hospitalarias, farmacias minoristas, farmacias en línea y otras): tendencias de la industria y pronóstico hasta 2029

Mercado de tratamiento de la migraña

Análisis y tamaño del mercado

La migraña es una enfermedad cerebral frecuente que puede resultar debilitante. El dolor de cabeza representa el 4,4 por ciento de todas las visitas al médico general, casi el 5 por ciento de todos los ingresos hospitalarios por motivos médicos y más del 20 por ciento de las consultas ambulatorias de neurología. La migraña afecta a alrededor del 20 por ciento de las personas en algún momento de sus vidas; la investigación epidemiológica revela que el 4,5 por ciento de la población de Europa occidental sufre dolores de cabeza al menos 15 días al mes, mientras que los estudios globales sugieren que alrededor del 1 por ciento de la población mundial sufre migraña crónica.

Data Bridge Market Research analiza que el mercado de tratamiento de la migraña, que fue de USD 2.38 mil millones en 2021, se disparará hasta USD 4.67 mil millones para 2029, y se espera que experimente una CAGR del 8,80% durante el período de pronóstico de 2022 a 2029. Además de los conocimientos del mercado, como el valor de mercado, la tasa de crecimiento, los segmentos del mercado, la cobertura geográfica, los actores del mercado y el escenario del mercado, el informe de mercado curado por el equipo de Data Bridge Market Research también incluye un análisis experto en profundidad, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance del informe y segmentación del mercado

Métrica del informe

Detalles

Período de pronóstico

2022 a 2029

Año base

2021

Años históricos

2020 (Personalizable para 2014 - 2019)

Unidades cuantitativas

Ingresos en miles de millones de USD, volúmenes en unidades, precios en USD

Segmentos cubiertos

Tipos (Episódica, Migraña con Aura, Crónica y Otras), Tratamiento (Tratamiento Agudo/Abortivo, Tratamiento Preventivo/Profiláctico, Terapias y Dispositivos No Farmacológicos), Vía de Administración (Oral, Parenteral, Aerosoles Nasales y Otros), Tipo de Producto (Recetado y de Venta Libre), Tipo (De Marca y Genérico), Usuario Final (Hospitales, Clínicas, Atención Domiciliaria, Otros), Canal de Distribución (Farmacias Hospitalarias, Farmacias Minoristas, Farmacias Online y Otros)

Países cubiertos

EE. UU., Canadá y México en América del Norte, Alemania, Francia, Reino Unido, Países Bajos, Suiza, Bélgica, Rusia, Italia, España, Turquía, Resto de Europa en Europa, China, Japón, India, Corea del Sur, Singapur, Malasia, Australia, Tailandia, Indonesia, Filipinas, Resto de Asia-Pacífico (APAC) en Asia-Pacífico (APAC), Arabia Saudita, Emiratos Árabes Unidos, Sudáfrica, Egipto, Israel, Resto de Medio Oriente y África (MEA) como parte de Medio Oriente y África (MEA), Brasil, Argentina y Resto de América del Sur como parte de América del Sur

Actores del mercado cubiertos

Pfizer Inc. (EE. UU.), Eli Lilly and Company (EE. UU.), Amgen Inc. (EE. UU.), GlaxoSmithKline plc. (Reino Unido), Novartis AG (Suiza), Bayer AG (Alemania), Allergan (Irlanda), Abbott (EE. UU.), Allodynic Therapeutics, LLC (EE. UU.), AOBiome (EE. UU.), AstraZeneca (Reino Unido), Aurobindo Pharma USA (EE. UU.), Bausch Health Companies Inc. (Canadá), Biohaven Pharmaceuticals (EE. UU.), Boehringer Ingelheim International GmbH (Alemania), Catalent, Inc (EE. UU.), Dr. Reddy's Laboratories Ltd. (India), Impel Pharmaceuticals Inc. (EE. UU.), H. Lundbeck A/S (Dinamarca), Merck & Co., Inc (EE. UU.)

Oportunidades de mercado
  • Mayor inversión en investigación y desarrollo (I+D) que conduce a productos en desarrollo
  •  Demanda creciente y avance tecnológico para el tratamiento de la migraña aguda

Definición de mercado

La migraña es una enfermedad neurológica devastadora que se caracteriza por ataques recurrentes de dolor de cabeza intenso y punzante que pueden durar más de tres días. Los dolores de cabeza, que suelen ser unilaterales, pueden durar de cuatro horas a tres días. Otros síntomas, como náuseas, aumento de la sensibilidad al sonido (fonofobia), vómitos, aumento de la sensibilidad a la luz (fotofobia), hormigueo o entumecimiento en las extremidades o las piernas, sudoración y diarrea, se asocian frecuentemente al dolor.

Dinámica del mercado de tratamiento de la migraña

Conductores

• Aumento de la prevalencia y el diagnóstico de la migraña.

Uno de los principales factores que impulsan la expansión del mercado es el enorme aumento de los casos de migraña. Además, el mercado se está beneficiando de las mejores políticas de reembolso para los tratamientos de la migraña y de la creciente demanda de medicamentos de precisión. La creciente demanda de dispositivos de estimulación nerviosa eléctrica para tratar las migrañas y la aprobación prevista de nuevas clases de fármacos en fase avanzada con mayor eficacia clínica, como la introducción de los anticuerpos monoclonales contra el péptido relacionado con el gen de la calcitonina (CGRP) , están impulsando el crecimiento del mercado.

• Se están logrando avances significativos en el tratamiento preventivo de la migraña crónica.

Los avances significativos deberían reconsiderar los enfoques de esta enfermedad devastadora y permitirnos permanecer atentos y continuar con la investigación clínica científica, teniendo en cuenta también que solo una estrategia de gestión clínica y científica común y compartida mejorará la detección de la migraña crónica. Esto distingue fenotipos y marcadores biológicos y arroja luz sobre áreas de gobernanza clínica desatendidas. Depende de nosotros asegurar que las alternativas de tratamiento nuevas y en desarrollo, como los anticuerpos monoclonales anti-CGRP y OBT-A, se exploten en todo su potencial dentro de una cultura preventiva más amplia para minimizar drásticamente los costos personales, sociales y económicos de esta enfermedad mortal.

  • Conciencia creciente sobre la migraña

The increased awareness of migraine and the multiple treatment choices available are the primary drivers of the global migraine treatment market growth in the near future. A number of organisations, like the American Headache and Migraine Association, are attempting to raise awareness of migraine by developing programmes and providing assistance to patients in order to raise knowledge about the disease and other headache diseases. A lot of vendors are going to invest in migraine medications research and development (R&D) as a result of the rising number of migraine incidences and unmet demands in the global migraine treatment market. As a result, the worldwide migraine medications market is expected to grow in the forecast period of 2022 to 2029.

Opportunities

Migraine treatment includes features such as increased research and development (R&D) investment leading to pipeline products, which will result in manufacturers launching new products into the market, increasing demand, and technological advancement for the treatment of acute migraine has increased. Various research studies are now underway, which are likely to give producers a competitive advantage in developing new, innovative, and improved migraine treatment medications and other opportunities in the migraine treatment market.

Restraints/Challenges

However, alternative therapies such as homeopathy and limitations of current migraine therapies, decline in clinical visits and procedural treatment of migraines due to social distancing norms are expected to restrain the market growth in the forecast period 2022 to 2029.

This migraine treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the migraine treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Migraine Treatment Market

COVID-19's neurologic signs point to the virus entering the neurological system via the olfactory groove or the circulation. COVID-19 mortality has been linked to cardiac and pulmonary illnesses in numerous studies. Furthermore, migraine causes a larger burden of vascular disorders, putting migraine sufferers at a higher risk of poor COVID-19 outcomes. A migraine attack can be triggered by COVID-19 acute symptoms such as fever, sleep difficulty, and dehydration. COVID-19 headaches were described as pulsing, pressing, or stabbing in nature, and were mostly bilateral, lasting longer, resistant to analgesia, and more common in males. This makes migraine sufferers particularly vulnerable to the pandemic's long-term and indirect consequences, such as low mood, post-viral exhaustion, and anxiety.

Recent Development

  • According to Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc., Rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, earned a favourable opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) in February 2022. The 75 mg dose of Rimegepant (available as an orally dissolving tablet) is suggested for marketing authorization for the acute treatment of migraine with or without aura in adults and the preventative treatment for episodic migraine in adults who experience at least four migraine attacks per month.
  • In January 2022, Elyxyb (celecoxib oral solution) is a novel fast-acting liquid from BioDelivery Sciences. It's one of the first FDA-approved ready-to-use oral treatments for individuals suffering from acute migraine with or without aura.

Global Migraine Treatment Market Scope

The migraine treatment market is segmented on the basis of type, treatment, route of administration, product, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

  • Episodic
  • Migraine with Aura
  • Chronic
  • Others 

Treatment

  • Acute/Abortive Treatment
  • Preventive/prophylactic Treatment 
  • Non-Pharmacological Therapies and Devices

Route of Administration

  • Oral
  • Parenteral

 Product

  • Prescription
  • Over The Counter

Type

  • Branded
  • Generic

 End-User

  • Hospitals
  • Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital-Based Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Migraine Treatment Market Regional Analysis/Insights

The migraine treatment market is analysed and market size insights and trends are provided by country, type, treatment, route of administration, product, distribution channel and end-user as referenced above.

Los países cubiertos en el informe del mercado de tratamiento de la migraña son EE. UU., Canadá y México en América del Norte, Alemania, Francia, Reino Unido, Países Bajos, Suiza, Bélgica, Rusia, Italia, España, Turquía, Resto de Europa en Europa, China, Japón, India, Corea del Sur, Singapur, Malasia, Australia, Tailandia, Indonesia, Filipinas, Resto de Asia-Pacífico (APAC) en Asia-Pacífico (APAC), Arabia Saudita, Emiratos Árabes Unidos, Sudáfrica, Egipto, Israel, Resto de Medio Oriente y África (MEA) como parte de Medio Oriente y África (MEA), Brasil, Argentina y Resto de América del Sur como parte de América del Sur.

América del Norte es una región dominante en el mercado mundial de tratamiento de la migraña. La presencia de un sector farmacéutico bien establecido en la región es una razón importante de la sólida posición de América del Norte en el mercado mundial de tratamiento de la migraña. Además, debido a un gran conocimiento de los peligros de la migraña y de cómo afecta a la calidad de vida, existe una necesidad sustancial de medicamentos para la migraña en la región.

La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Puntos de datos como análisis de la cadena de valor aguas abajo y aguas arriba, tendencias técnicas y análisis de las cinco fuerzas de Porter, estudios de casos son algunos de los indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas globales y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los aranceles nacionales y las rutas comerciales se consideran al proporcionar un análisis de pronóstico de los datos del país. 

Crecimiento de la infraestructura de salud Base instalada y penetración de nuevas tecnologías

El mercado de tratamiento de la migraña también le proporciona un análisis detallado del mercado para cada país: crecimiento del gasto sanitario en equipos de capital, base instalada de diferentes tipos de productos para el mercado de tratamiento de la migraña, impacto de la tecnología mediante curvas de línea de vida y cambios en los escenarios regulatorios de la atención médica y su impacto en el mercado de tratamiento de la migraña. Los datos están disponibles para el período histórico 2010-2020.

Análisis del panorama competitivo y de la cuota de mercado del tratamiento de la migraña

El panorama competitivo del mercado de tratamiento de la migraña proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y la variedad de productos, el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado de tratamiento de la migraña.

Algunos de los principales actores que operan en el mercado del tratamiento de la migraña son:

  • Pfizer Inc. (Estados Unidos)
  • Eli Lilly and Company (Estados Unidos)
  • Amgen Inc. (Estados Unidos)
  • GlaxoSmithKline plc. (Reino Unido)
  • Novartis AG (Suiza)
  • Bayer AG (Alemania)
  • Allergan (Irlanda)
  • Abbott (Estados Unidos)
  • Allodynic Therapeutics, LLC (Estados Unidos)
  • AOBiome (Estados Unidos)
  • AstraZeneca (Reino Unido)
  • Aurobindo Pharma USA (Estados Unidos)
  • Bausch Health Companies Inc. (Canadá)
  • Biohaven Pharmaceuticals (Estados Unidos)
  • Boehringer Ingelheim International GmbH (Alemania)
  • Catalent, Inc. (Estados Unidos)
  • Laboratorios Dr. Reddy Ltd. (India)
  • Impel Pharmaceuticals Inc. (Estados Unidos)
  • H. Lundbeck A/S (Dinamarca)
  • Merck & Co., Inc (Estados Unidos)

SKU-

Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo

Sample Image Click on image to enlarge
  • Panel de análisis de datos interactivo
  • Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
  • Acceso de analista de investigación para personalización y consultas
  • Análisis de la competencia con panel interactivo
  • Últimas noticias, actualizaciones y análisis de tendencias
  • Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Solicitud de demostración

Tabla de contenido

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL MIGRAINE TREATMENT MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPES OF MIGRAINE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.1.1 INCREASING PREVALENCE OF MIGRAINE

3.1.2 GROWING FEMALE POPULATION

3.1.3 DEVELOPMENT OF NOVEL DRUGS

3.1.4 RISING AWARENESS PROGRAMS

3.1.5 AVAILABILITY OF LARGE NUMBER OF GENERIC DRUGS

3.2 RESTRAINTS

3.2.1 RECALL OF DRUGS

3.2.2 ADVERSE EFFECTS OF DRUGS

3.3 OPPORTUNITIES

3.3.1 TECHNOLOGICAL ADVANCEMENTS FOR THE TREATMENT OF ACUTE MIGRAINE

3.3.2 INCREASING R&D INVESTMENT LEADING TO PIPELINE PRODUCTS

3.3.3 RISING COLLABORATIONS, AND MERGER & ACQUISITIONS AMONG THE MARKET PLAYERS

3.4 CHALLENGES

3.4.1 USE OF ALTERNATIVE THERAPIES SUCH AS HOMEOPATHY

3.4.2 LIMITATIONS OF CURRENT MIGRAINE THERAPIES

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

6 EPIDEMIOLOGY

7 REIMBURSEMENT SCENARIO & REGULATION STATUS

7.1 REIMBURSEMENT SCENARIO

7.2 REGULATIONS

8 PIPELINE ANALYSIS

9 IMPACT OF COVID 19 PANDEMIC ON THE MARKET

9.1 PRICE IMPACT

9.2 IMPACT ON DEMAND

9.3 IMPACT ON SUPPLY CHAIN

9.4 STRATEGIC DECISIONS FOR MANUFACTURERS

9.5 CONCLUSION

10 GLOBAL MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE

10.1 OVERVIEW

10.2 EPISODIC

10.3 MIGRAINE WITH AURA

10.4 CHRONIC

10.5 OTHERS

11 GLOBAL MIGRAINE TREATMENT MARKET, BY TREATMENT

11.1 OVERVIEW

11.2 ACUTE/ABORTIVE TREATMENT

11.2.1 NONSPECIFIC THERAPIES

11.2.1.1 TRIPTANS

11.2.1.1.1 SUMATRIPTAN

11.2.1.1.2 RIZATRIPTAN

11.2.1.1.3 OTHERS

11.2.1.2 OPIATES/OPOIDS

11.2.1.2.1 VICODIN

11.2.1.2.2 OXYCONTIN

11.2.1.2.3 PERCOCET

11.2.1.2.4 OTHERS

11.2.1.3 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS

11.2.1.3.1 ASPIRIN

11.2.1.3.2 IBUPROFEN

11.2.1.3.3 ACETAMINOPHEN

11.2.1.3.4 OTHERS

11.2.1.4 ERGOT ALKALOID

11.2.1.4.1 ERGOTAMINE

11.2.1.4.2 LASMIDITAN

11.2.1.4.3 DIHYDROERGOTAMINES

11.2.1.4.4 OTHERS

11.2.1.5 ANTI-NAUSEA

11.2.1.5.1 PROCHLORPERAZINE

11.2.1.5.2 METOCLOPRAMIDE

11.2.1.5.3 CHLORPROMAZINE

11.2.1.5.4 OTHERS

11.2.1.6 OTHERS

11.2.2 ADJUNCTIVE THERAPIES

11.2.2.1 ANTIEMETICS

11.2.2.2 SEDATIVES

11.2.2.3 OTHERS

11.2.3 OTHERS

11.2.3.1 INTRANASAL LIDOCAINE

11.2.3.2 STEROIDS

11.2.3.3 OTHERS

11.3 PREVENTIVE/PROPHYLACTIC TREATMENT

11.3.1 ANTICONVULSANTS

11.3.1.1 TOPAMAX (TOPIRAMATE)

11.3.1.2 TROKENDI (TOPIRAMATE)

11.3.1.3 DEPAKOTE (DIVALPROEX SODIUM)

11.3.1.4 QUDEXY XR (TOPIRAMATE)

11.3.1.5 OTHERS

11.3.2 CALCITONIN GENE-RELATED PEPTIDE THERAPY

11.3.2.1 ERENUMAB-AOOE

11.3.2.2 GALCANEZUMAB

11.3.2.3 FREMANEZUMAB-VFRM

11.3.2.4 OTHERS

11.3.3 SELECTIVE SEROTONIN RECEPTOR AGONISTS

11.3.3.1 SUMATRIPTAN

11.3.3.2 RIZATRIPTAN

11.3.3.3 ZOLMITRIPTAN

11.3.3.4 ELETRIPTAN

11.3.3.5 FROVATRIPTAN

11.3.3.6 NARATRIPTAN

11.3.3.7 ALMOTRIPTAN MALATE

11.3.3.8 OTHERS

11.3.4 ANTIDEPRESSANTS

11.3.4.1 AMITRIPTYLINE

11.3.4.2 NORTRIPTYLINE

11.3.4.3 OTHERS

11.3.5 NSAIDS

11.3.5.1 NAPROXEN SODIUM

11.3.5.2 NAPROXEN

11.3.5.3 KETOPROFEN

11.3.5.4 FENOPROFEN

11.3.5.5 OTHERS

11.3.6 BLOOD PRESSURE-LOWERING MEDICATIONS

11.3.6.1 BETA BLOCKERS

11.3.6.1.1 PROPRANAOLOL

11.3.6.1.2 TIMOLOL

11.3.6.1.3 OTHERS

11.3.6.2 CALCIUM-CHANNEL BLOCKERS

11.3.6.2.1 VERAPAMIL

11.3.6.2.2 NIMODIPINE

11.3.6.2.3 OTHERS

11.3.7 ANGIOTENSIN BLOCKERS: ACE-IS/ARBS

11.3.7.1 CANDESARTAN

11.3.7.2 TELMISARTAN

11.3.7.3 OTHERS

11.3.8 OTHERS

11.4 NON-PHARMACOLOGICAL THERAPIES

11.4.1 ACUPUNCTURE

11.4.2 BIOFEEDBACK TECHNIQUES

11.4.3 COGNITIVE BEHAVIOR THERAPY

11.4.4 MASSAGE

11.4.5 RELAXATION

11.4.6 OTHERS

11.5 DEVICES

11.5.1 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS)

11.5.2 OTHERS

12 GLOBAL MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

12.1 OVERVIEW

12.2 ORAL

12.3 PARENTERAL

12.4 NASAL SPRAYS

12.5 OTHERS

 

13 GLOBAL MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE

13.1 OVERVIEW

13.2 PRESCRIPTION

13.3 OVER THE COUNTER

14 GLOBAL MIGRAINE TREATMENT MARKET, BY TYPE

14.1 OVERVIEW

14.2 GENERIC

14.3 BRANDED

15 GLOBAL MIGRAINE TREATMENT MARKET, BY END USER

15.1 OVERVIEW

15.2 HOSPITALS

15.3 CLINICS

15.4 HOMECARE

15.5 OTHERS

16 GLOBAL MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL

16.1 OVERVIEW

16.2 HOSPITAL PHARMACIES

16.3 RETAIL PHARMACIES

16.4 ONLINE PHARMACIES

16.5 OTHERS

17 GLOBAL MIGRAINE TREATMENT MARKET, BY GEOGRAPHY

17.1 OVERVIEW

17.2 NORTH AMERICA

17.2.1 U.S.

17.2.2 CANADA

17.2.3 MEXICO

17.3 EUROPE

17.3.1 GERMANY

17.3.2 U.K.

17.3.3 FRANCE

17.3.4 ITALY

17.3.5 SPAIN

17.3.6 NETHERLANDS

17.3.7 RUSSIA

17.3.8 SWITZERLAND

17.3.9 BELGIUM

17.3.10 TURKEY

17.3.11 AUSTRIA

17.3.12 NORWAY

17.3.13 HUNGARY

17.3.14 LITHUANIA

17.3.15 IRELAND

17.3.16 POLAND

17.3.17 REST OF EUROPE

17.4 ASIA-PACIFIC

17.4.1 CHINA

17.4.2 JAPAN

17.4.3 INDIA

17.4.4 SOUTH KOREA

17.4.5 AUSTRALIA

17.4.6 SINGAPORE

17.4.7 INDONESIA

17.4.8 THAILAND

17.4.9 MALAYSIA

17.4.10 PHILIPPINES

17.4.11 VIETNAM

17.4.12 REST OF ASIA-PACIFIC

17.5 SOUTH AMERICA

17.5.1 BRAZIL

17.5.2 ARGENTINA

17.5.3 PERU

17.5.4 REST OF SOUTH AMERICA

17.6 MIDDLE EAST & AFRICA

17.6.1 SAUDI ARABIA

17.6.2 SOUTH AFRICA

17.6.3 UAE

17.6.4 ISRAEL

17.6.5 KUWAIT

17.6.6 EGYPT

17.6.7 REST OF MIDDLE EAST & AFRICA

18 GLOBAL MIGRAINE TREATMENT MARKET, COMPANY LANDSCAPE

18.1 COMPANY SHARE ANALYSIS: GLOBAL

18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

18.3 COMPANY SHARE ANALYSIS: EUROPE

18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

 

19 SWOT ANALYSIS AND DATA BRIDGE MARKET RESEARCH ANALYSIS

19.1 SWOT ANALYSIS

19.1.1 STRENGTH

19.1.1.1 STRONG PRODUCT PORTFOLIO

19.1.1.2 GLOBAL COMMERCIAL PRESENCE IN EMERGING MARKETS

19.1.2 WEAKNESS

19.1.2.1 DEPENDENCY ON THIRD PARTIES FOR RESEARCH AND DEVELOPMENT

19.1.2.2 LITIGATION AND GOVERNMENT INVESTIGATION

19.1.3 OPPORTUNITY

19.1.3.1 EXPANDING BUSINESS THOROUGH THEIR SUBSIDIARIES

19.1.3.2 STRATEGIC INITIATIVES

19.1.4 THREAT

19.1.4.1 COMPETITIVE ENVIRONMENT

19.2 GLOBAL MIGRAINE TREATMENT MARKET: DBMR ANALYSIS

20 COMPANY PROFILE

20.1 AMGEN INC.

20.1.1 COMPANY SNAPSHOT

20.1.2 REVENUE ANALYSIS

20.1.3 COMPANY SHARE ANALYSIS

20.1.4 PRODUCT PORTFOLIO

20.1.5 RECENT DEVELOPMENTS

20.2 ELI LILLY AND COMPANY

20.2.1 COMPANY SNAPSHOT

20.2.2 REVENUE ANALYSIS

20.2.3 COMPANY SHARE ANALYSIS

20.2.4 PRODUCT PORTFOLIO

20.2.5 RECENT DEVELOPMENTS

20.3 GLAXOSMITHKLINE PLC.

20.3.1 COMPANY SNAPSHOT

20.3.2 REVENUE ANALYSIS

20.3.3 COMPANY SHARE ANALYSIS

20.3.4 PRODUCT PORTFOLIO

20.3.5 RECENT DEVELOPMENTS

20.4 NOVARTIS AG

20.4.1 COMPANY SNAPSHOT

20.4.2 REVENUE ANALYSIS

20.4.3 COMPANY SHARE ANALYSIS

20.4.4 PRODUCT PORTFOLIO

20.4.5 RECENT DEVELOPMENTS

 

20.5 BAYER AG

20.5.1 COMPANY SNAPSHOT

20.5.2 REVENUE ANALYSIS

20.5.3 COMPANY SHARE ANALYSIS

20.5.4 PRODUCT PORTFOLIO

20.5.5 RECENT DEVELOPMENT

20.6 ALLERGAN

20.6.1 COMPANY SNAPSHOT

20.6.2 REVENUE ANALYSIS

20.6.3 PRODUCT PORTFOLIO

20.6.4 RECENT DEVELOPMENTS

20.7 ABBOTT

20.7.1 COMPANY SNAPSHOT

20.7.2 REVENUE ANALYSIS

20.7.3 PRODUCT PORTFOLIO

20.7.4 RECENT DEVELOPMENTS

20.8 ALLODYNIC THERAPEUTICS, LLC

20.8.1 COMPANY SNAPSHOT

20.8.2 PRODUCT PORTFOLIO

20.8.3 RECENT DEVELOPMENT

20.9 AOBIOME

20.9.1 COMPANY SNAPSHOT

20.9.2 PRODUCT PORTFOLIO

20.9.3 RECENT DEVELOPMENTS

20.1 ASTRAZENECA

20.10.1 COMPANY SNAPSHOT

20.10.2 REVENUE ANALYSIS

20.10.3 PRODUCT PORTFOLIO

20.10.4 RECENT DEVELOPMENTS

20.11 AUROBINDO PHARMA USA (A SUBSIDIARY OF AUROBINDO PHARMA)

20.11.1 COMPANY SNAPSHOT

20.11.2 REVENUE ANALYSIS

20.11.3 PRODUCT PORTFOLIO

20.11.4 RECENT DEVELOPMENTS

20.12 BAUSCH HEALTH COMPANIES INC.

20.12.1 COMPANY SNAPSHOT

20.12.2 REVENUE ANALYSIS

20.12.3 PRODUCT PORTFOLIO

20.12.4 RECENT DEVELOPMENT

 

20.13 BIOHAVEN PHARMACEUTICALS

20.13.1 COMPANY SNAPSHOT

20.13.2 REVENUE ANALYSIS

20.13.3 PRODUCT PORTFOLIO

20.13.4 RECENT DEVELOPMENTS

20.14 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

20.14.1 COMPANY SNAPSHOT

20.14.2 REVENUE ANALYSIS

20.14.3 PRODUCT PORTFOLIO

20.14.4 RECENT DEVELOPMENTS

20.15 CATALENT, INC

20.15.1 COMPANY SNAPSHOT

20.15.2 REVENUE ANALYSIS

20.15.3 PRODUCT PORTFOLIO

20.15.4 RECENT DEVELOPMENTS

20.16 DR. REDDY’S LABORATORIES LTD.

20.16.1 COMPANY SNAPSHOT

20.16.2 REVENUE ANALYSIS

20.16.3 PRODUCT PORTFOLIO

20.16.4 RECENT DEVELOPMENTS

20.17 IMPEL NEUROPHARMA, INC.

20.17.1 COMPANY SNAPSHOT

20.17.2 PRODUCT PORTFOLIO

20.17.3 RECENT DEVELOPMENTS

20.18 LUNDBECK

20.18.1 COMPANY SNAPSHOT

20.18.2 REVENUE ANALYSIS

20.18.3 PRODUCT PORTFOLIO

20.18.4 RECENT DEVELOPMENTS

20.19 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)

20.19.1 COMPANY SNAPSHOT

20.19.2 REVENUE ANALYSIS

20.19.3 PRODUCT PORTFOLIO

20.19.4 RECENT DEVELOPMENTS

20.2 NEURELIS, INC.

20.20.1 COMPANY SNAPSHOT

20.20.2 PRODUCT PORTFOLIO

20.20.3 RECENT DEVELOPMENTS

 

20.21 OTSUKA PHARMACEUTICAL CO., LTD. (A SUBSIDIARY OF OTSUKA HOLDINGS CO., LTD.)

20.21.1 COMPANY SNAPSHOT

20.21.2 REVENUE ANALYSIS

20.21.3 PRODUCT PORTFOLIO

20.21.4 RECENT DEVELOPMENTS

20.22 PFIZER INC.

20.22.1 COMPANY SNAPSHOT

20.22.2 REVENUE ANALYSIS

20.22.3 PRODUCT PORTFOLIO

20.22.4 RECENT DEVELOPMENTS

20.23 SUN PHARMACEUTICAL INDUSTRIES LTD.

20.23.1 COMPANY SNAPSHOT

20.23.2 REVENUE ANALYSIS

20.23.3 PRODUCT PORTFOLIO

20.23.4 RECENT DEVELOPMENTS

20.24 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICALS INDUSTRIES LTD.)

20.24.1 COMPANY SNAPSHOT

20.24.2 REVENUE ANALYSIS

20.24.3 PRODUCT PORTFOLIO

20.24.4 RECENT DEVELOPMENTS

20.25 ZOSANO PHARMA CORPORATION

20.25.1 COMPANY SNAPSHOT

20.25.2 REVENUE ANALYSIS

20.25.3 PRODUCT PORTFOLIO

20.25.4 RECENT DEVELOPMENTS

21 CONCLUSION

22 QUESTIONNAIRE

23 RELATED REPORTS

Lista de Tablas

LIST OF TABLES 

TABLE 1 GENERIC DRUGS FOR MIGRAINE TREATMENT

TABLE 2 PIPELINE DRUGS FOR MIGRAINE TREATMENT

TABLE 3 GLOBAL MIGRAINE TREATMENT MARKET, BY PIPELINE ANALYSIS

TABLE 4 GLOBAL MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 5 GLOBAL EPISODIC IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 6 GLOBAL MIGRAINE WITH AURA IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 7 GLOBAL CHRONIC IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 8 GLOBAL OTHERS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 9 GLOBAL MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 10 GLOBAL ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 11 GLOBAL ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 12 GLOBAL NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TRAETMENT, 2018-2027 (USD MILLION)

TABLE 13 GLOBAL TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 14 GLOBAL OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 15 GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 16 GLOBAL ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 17 GLOBAL ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 18 GLOBAL ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 19 GLOBAL OTHERS IN MIGRAINE TREATMENT MARKET, BY TRATMENT, 2018-2027 (USD MILLION)

TABLE 20 GLOBAL PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 21 GLOBAL PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 22 GLOBAL ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 23 GLOBAL CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 24 GLOBAL SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 25 GLOBAL ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 26 GLOBAL NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 27 GLOBAL BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 28 GLOBAL BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 29 GLOBAL CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 30 GLOBAL ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 31 GLOBAL NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 32 GLOBAL NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 33 GLOBAL DEVICES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 34 GLOBAL DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 35 GLOBAL MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 36 GLOBAL ORAL IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 37 GLOBAL PARENTERAL IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 38 GLOBAL NASAL SPRAYS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 39 GLOBAL OTHERS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 40 GLOBAL MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 41 GLOBAL PRESCRIPTION IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 42 GLOBAL OVER THE COUNTER IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 43 GLOBAL MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 44 GLOBAL GENERIC IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 45 GLOBAL BRANDED IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 46 GLOBAL MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 47 GLOBAL HOSPITALS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 48 GLOBAL CLINICS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 49 GLOBAL HOMECARE IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 50 GLOBAL OTHERS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 51 GLOBAL MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 52 GLOBAL HOSPITAL PHARMACIES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 53 GLOBAL RETAIL PHARMACIES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 54 GLOBAL ONLINE PHARMACIES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 55 GLOBAL OTHERS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 56 GLOBAL MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 57 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 58 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 59 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 60 NORTH AMERICA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 61 NORTH AMERICA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 62 NORTH AMERICA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 63 NORTH AMERICA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 64 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 65 NORTH AMERICA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 66 NORTH AMERICA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 67 NORTH AMERICA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 68 NORTH AMERICA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 69 NORTH AMERICA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 70 NORTH AMERICA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 71 NORTH AMERICA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 72 NORTH AMERICA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 73 NORTH AMERICA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 74 NORTH AMERICA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 75 NORTH AMERICA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 76 NORTH AMERICA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 77 NORTH AMERICA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 78 NORTH AMERICA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 79 NORTH AMERICA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 80 NORTH AMERICA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 81 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 82 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 83 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 84 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 85 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 86 U.S. MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 87 U.S. MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 88 U.S. ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 89 U.S. NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 90 U.S. TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 91 U.S. OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 92 U.S. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 93 U.S. ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 94 U.S. ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 95 U.S. ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 96 U.S. OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 97 U.S. PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 98 U.S. ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 99 U.S. CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD)

TABLE 100 U.S. SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 101 U.S. ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 102 U.S. NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 103 U.S. BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 104 U.S. BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 105 U.S. CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 106 U.S. ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 107 U.S. NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 108 U.S. DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 109 U.S. MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 110 U.S. MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 111 U.S. MIGRAINE TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 112 U.S. MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 113 U.S. MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 114 CANADA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 115 CANADA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 116 CANADA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 117 CANADA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 118 CANADA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 119 CANADA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 120 CANADA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 121 CANADA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 122 CANADA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 123 CANADA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 124 CANADA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 125 CANADA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 126 CANADA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 127 CANADA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 128 CANADA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 129 CANADA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 130 CANADA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 131 CANADA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 132 CANADA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 133 CANADA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 134 CANADA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 135 CANADA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 136 CANADA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 137 CANADA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 138 CANADA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 139 CANADA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 140 CANADA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 141 CANADA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 142 MEXICO MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 143 MEXICO MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 144 MEXICO ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 145 MEXICO NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 146 MEXICO TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 147 MEXICO OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 148 MEXICO NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 149 MEXICO ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 150 MEXICO ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 151 MEXICO ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 152 MEXICO OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 153 MEXICO PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 154 MEXICO ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 155 MEXICO CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 156 MEXICO SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 157 MEXICO ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 158 MEXICO NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 159 MEXICO BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 160 MEXICO BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 161 MEXICO CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 162 MEXICO ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 163 MEXICO NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 164 MEXICO DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 165 MEXICO MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 166 MEXICO MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 167 MEXICO MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 168 MEXICO MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 169 MEXICO MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 170 EUROPE MIGRAINE TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 171 EUROPE MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 172 EUROPE MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 173 EUROPE ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 174 EUROPE NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 175 EUROPE TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 176 EUROPE OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 177 EUROPE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 178 EUROPE ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 179 EUROPE ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 180 EUROPE ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 181 EUROPE OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 182 EUROPE PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 183 EUROPE ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 184 EUROPE CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 185 EUROPE SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 186 EUROPE ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 187 EUROPE NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 188 EUROPE BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 189 EUROPE BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 190 EUROPE CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 191 EUROPE ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 192 EUROPE NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 193 EUROPE DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 194 EUROPE MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 195 EUROPE MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 196 EUROPE MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 197 EUROPE MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 198 EUROPE MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 199 GERMANY MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 200 GERMANY MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 201 GERMANY ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 202 GERMANY NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 203 GERMANY TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 204 GERMANY OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 205 GERMANY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 206 GERMANY ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 207 GERMANY ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 208 GERMANY ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 209 GERMANY OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 210 GERMANY PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 211 GERMANY ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 212 GERMANY CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD)

TABLE 213 GERMANY SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 214 GERMANY ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 215 GERMANY NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 216 GERMANY BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 217 GERMANY BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 218 GERMANY CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 219 GERMANY ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 220 GERMANY NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 221 EUROPE DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 222 GERMANY MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 223 GERMANY MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 224 GERMANY MIGRAINE TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 225 GERMANY MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 226 GERMANY MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 227 U.K. MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 228 U.K. MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 229 U.K. ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 230 U.K. NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 231 U.K. TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 232 U.K. OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 233 U.K. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 234 U.K. ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 235 U.K. ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 236 U.K. ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 237 U.K. OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 238 U.K. PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 239 U.K. ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 240 U.K. CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 241 U.K. SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 242 U.K. ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 243 U.K. NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 244 U.K. BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 245 U.K. BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 246 U.K. CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 247 U.K. ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 248 U.K. NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 249 U.K. DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 250 U.K. MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 251 U.K. MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 252 U.K. MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 253 U.K. MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 254 U.K. MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 255 FRANCE MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 256 FRANCE MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 257 FRANCE ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 258 FRANCE NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 259 FRANCE TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 260 FRANCE OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 261 FRANCE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 262 FRANCE ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 263 FRANCE ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 264 FRANCE ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 265 FRANCE OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 266 FRANCE PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 267 FRANCE ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 268 FRANCE CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 269 FRANCE SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 270 FRANCE ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 271 FRANCE NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 272 FRANCE BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 273 FRANCE BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 274 FRANCE CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 275 FRANCE ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 276 FRANCE NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 277 FRANCE DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 278 FRANCE MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 279 FRANCE MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 280 FRANCE MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 281 FRANCE MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 282 FRANCE MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 283 ITALY MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 284 ITALY MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 285 ITALY ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 286 ITALY NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 287 ITALY TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 288 ITALY OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 289 ITALY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 290 ITALY ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 291 ITALY ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 292 ITALY ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 293 ITALY OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 294 ITALY PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 295 ITALY ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 296 ITALY CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 297 ITALY SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 298 ITALY ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 299 ITALY NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 300 ITALY BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 301 ITALY BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 302 ITALY CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 303 ITALY ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 304 ITALY NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 305 ITALY DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 306 ITALY MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 307 ITALY MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 308 ITALY MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 309 ITALY MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 310 ITALY MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 311 SPAIN MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 312 SPAIN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 313 SPAIN ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 314 SPAIN NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 315 SPAIN TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 316 SPAIN OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 317 SPAIN NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 318 SPAIN ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 319 SPAIN ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 320 SPAIN ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 321 SPAIN OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 322 SPAIN PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 323 SPAIN ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 324 SPAIN CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 325 SPAIN SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 326 SPAIN ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 327 SPAIN NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 328 SPAIN BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 329 SPAIN BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 330 SPAIN CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 331 SPAIN ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 332 SPAIN NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 333 SPAIN DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 334 SPAIN MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 335 SPAIN MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 336 SPAIN MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 337 SPAIN MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 338 SPAIN MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 339 NETHERLANDS MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 340 NETHERLANDS MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 341 NETHERLANDS ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 342 NETHERLANDS NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 343 NETHERLANDS TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 344 NETHERLANDS OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 345 NETHERLANDS NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 346 NETHERLANDS ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 347 NETHERLANDS ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 348 NETHERLANDS ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 349 NETHERLANDS OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 350 NETHERLANDS PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 351 NETHERLANDS ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 352 NETHERLANDS CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 353 NETHERLANDS SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 354 NETHERLANDS ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 355 NETHERLANDS NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 356 NETHERLANDS BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 357 NETHERLANDS BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 358 NETHERLANDS CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 359 NETHERLANDS ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 360 NETHERLANDS NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 361 NETHERLANDS DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 362 NETHERLANDS MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 363 NETHERLANDS MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 364 NETHERLANDS MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 365 NETHERLANDS MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 366 NETHERLANDS MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 367 RUSSIA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 368 RUSSIA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 369 RUSSIA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 370 RUSSIA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 371 RUSSIA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 372 RUSSIA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 373 RUSSIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 374 RUSSIA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 375 RUSSIA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 376 RUSSIA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 377 RUSSIA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 378 RUSSIA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 379 RUSSIA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 380 RUSSIA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 381 RUSSIA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 382 RUSSIA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 383 RUSSIA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 384 RUSSIA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 385 RUSSIA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 386 RUSSIA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 387 RUSSIA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 388 RUSSIA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 389 RUSSIA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 390 RUSSIA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 391 RUSSIA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 392 RUSSIA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 393 RUSSIA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 394 RUSSIA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 395 SWITZERLAND MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 396 SWITZERLAND MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 397 SWITZERLAND ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 398 SWITZERLAND NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 399 SWITZERLAND TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 400 SWITZERLAND OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 401 SWITZERLAND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 402 SWITZERLAND ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 403 SWITZERLAND ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 404 SWITZERLAND ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 405 SWITZERLAND OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 406 SWITZERLAND PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 407 SWITZERLAND ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 408 SWITZERLAND CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 409 SWITZERLAND SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 410 SWITZERLAND ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 411 SWITZERLAND NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 412 SWITZERLAND BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 413 SWITZERLAND BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 414 SWITZERLAND CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 415 SWITZERLAND ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 416 SWITZERLAND NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 417 SWITZERLAND DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 418 SWITZERLAND MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 419 SWITZERLAND MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 420 SWITZERLAND MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 421 SWITZERLAND MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 422 SWITZERLAND MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 423 BELGIUM MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 424 BELGIUM MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 425 BELGIUM ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 426 BELGIUM NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 427 BELGIUM TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 428 BELGIUM OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 429 BELGIUM NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 430 BELGIUM ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 431 BELGIUM ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 432 BELGIUM ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 433 BELGIUM OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 434 BELGIUM PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 435 BELGIUM ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 436 BELGIUM CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 437 BELGIUM SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 438 BELGIUM ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 439 BELGIUM NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 440 BELGIUM BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 441 BELGIUM BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 442 BELGIUM CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 443 BELGIUM ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 444 BELGIUM NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 445 BELGIUM DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 446 BELGIUM MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 447 BELGIUM MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 448 BELGIUM MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 449 BELGIUM MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 450 BELGIUM MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 451 TURKEY MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 452 TURKEY MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 453 TURKEY ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 454 TURKEY NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 455 TURKEY TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 456 TURKEY OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 457 TURKEY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 458 TURKEY ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 459 TURKEY ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 460 TURKEY ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 461 TURKEY OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 462 TURKEY PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 463 TURKEY ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 464 TURKEY CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 465 TURKEY SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 466 TURKEY ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 467 TURKEY NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 468 TURKEY BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 469 TURKEY BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 470 TURKEY CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 471 TURKEY ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 472 TURKEY NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 473 TURKEY DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 474 TURKEY MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 475 TURKEY MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 476 TURKEY MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 477 TURKEY MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 478 TURKEY MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 479 AUSTRIA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 480 AUSTRIA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 481 AUSTRIA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 482 AUSTRIA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 483 AUSTRIA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 484 AUSTRIA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 485 AUSTRIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 486 AUSTRIA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 487 AUSTRIA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 488 AUSTRIA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 489 AUSTRIA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 490 AUSTRIA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 491 AUSTRIA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 492 AUSTRIA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 493 AUSTRIA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 494 AUSTRIA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 495 AUSTRIA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 496 AUSTRIA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 497 AUSTRIA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 498 AUSTRIA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 499 AUSTRIA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 500 AUSTRIA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 501 AUSTRIA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 502 AUSTRIA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 503 AUSTRIA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 504 AUSTRIA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 505 AUSTRIA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 506 AUSTRIA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 507 NORWAY MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 508 NORWAY MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 509 NORWAY ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 510 NORWAY NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 511 NORWAY TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 512 NORWAY OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 513 NORWAY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 514 NORWAY ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 515 NORWAY ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 516 NORWAY ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 517 NORWAY OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 518 NORWAY PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 519 NORWAY ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 520 NORWAY CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 521 NORWAY SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 522 NORWAY ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 523 NORWAY NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 524 NORWAY BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 525 NORWAY BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 526 NORWAY CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 527 NORWAY ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 528 NORWAY NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 529 NORWAY DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 530 NORWAY MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 531 NORWAY MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 532 NORWAY MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 533 NORWAY MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 534 NORWAY MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 535 HUNGARY MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 536 HUNGARY MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 537 HUNGARY ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 538 HUNGARY NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 539 HUNGARY TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 540 HUNGARY OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 541 HUNGARY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 542 HUNGARY ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 543 HUNGARY ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 544 HUNGARY ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 545 HUNGARY OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 546 HUNGARY PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 547 HUNGARY ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 548 HUNGARY CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 549 HUNGARY SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 550 HUNGARY ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 551 HUNGARY NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 552 HUNGARY BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 553 HUNGARY BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 554 HUNGARY CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 555 HUNGARY ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 556 HUNGARY NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 557 HUNGARY DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 558 HUNGARY MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 559 HUNGARY MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 560 HUNGARY MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 561 HUNGARY MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 562 HUNGARY MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 563 LITHUANIA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 564 LITHUANIA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 565 LITHUANIA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 566 LITHUANIA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 567 LITHUANIA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 568 LITHUANIA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 569 LITHUANIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 570 LITHUANIA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 571 LITHUANIA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 572 LITHUANIA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 573 LITHUANIA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 574 LITHUANIA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 575 LITHUANIA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 576 LITHUANIA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 577 LITHUANIA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 578 LITHUANIA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 579 LITHUANIA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 580 LITHUANIA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 581 LITHUANIA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 582 LITHUANIA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 583 LITHUANIA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 584 LITHUANIA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 585 LITHUANIA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 586 LITHUANIA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 587 LITHUANIA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 588 LITHUANIA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 589 LITHUANIA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 590 LITHUANIA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 591 IRELAND MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 592 IRELAND MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 593 IRELAND ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 594 IRELAND NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 595 IRELAND TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 596 IRELAND OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 597 IRELAND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 598 IRELAND ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 599 IRELAND ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 600 IRELAND ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 601 IRELAND OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 602 IRELAND PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 603 IRELAND ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 604 IRELAND CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 605 IRELAND SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 606 IRELAND ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 607 IRELAND NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 608 IRELAND BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 609 IRELAND BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 610 IRELAND CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 611 IRELAND ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 612 IRELAND NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 613 IRELAND DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 614 IRELAND MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 615 IRELAND MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 616 IRELAND MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 617 IRELAND MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 618 IRELAND MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 619 POLAND MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 620 POLAND MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 621 POLAND ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 622 POLAND NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 623 POLAND TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 624 POLAND OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 625 POLAND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 626 POLAND ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 627 POLAND ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 628 POLAND ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 629 POLAND OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 630 POLAND PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 631 POLAND ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 632 POLAND CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 633 POLAND SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 634 POLAND ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 635 POLAND NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 636 POLAND BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 637 POLAND BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 638 POLAND CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 639 POLAND ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 640 POLAND NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 641 POLAND DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 642 POLAND MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 643 POLAND MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 644 POLAND MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 645 POLAND MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 646 POLAND MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 647 REST OF EUROPE MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 648 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 649 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 650 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 651 ASIA-PACIFIC ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 652 ASIA-PACIFIC NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 653 ASIA-PACIFIC TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 654 ASIA-PACIFIC OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 655 ASIA-PACIFIC NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 656 ASIA-PACIFIC ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 657 ASIA-PACIFIC ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 658 ASIA-PACIFIC ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 659 ASIA-PACIFIC OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 660 ASIA-PACIFIC PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 661 ASIA-PACIFIC ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 662 ASIA-PACIFIC CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 663 ASIA-PACIFIC SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 664 ASIA-PACIFIC ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 665 ASIA-PACIFIC NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 666 ASIA-PACIFIC BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 667 ASIA-PACIFIC BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 668 ASIA-PACIFIC CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 669 ASIA-PACIFIC ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 670 ASIA-PACIFIC NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 671 ASIA-PACIFIC DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 672 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 673 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 674 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 675 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 676 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 677 CHINA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 678 CHINA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 679 CHINA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 680 CHINA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 681 CHINA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 682 CHINA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 683 CHINA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 684 CHINA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 685 CHINA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 686 CHINA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 687 CHINA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 688 CHINA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 689 CHINA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 690 CHINA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD)

TABLE 691 CHINA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 692 CHINA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 693 CHINA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 694 CHINA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 695 CHINA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 696 CHINA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 697 CHINA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 698 CHINA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 699 CHINA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 700 CHINA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 701 CHINA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 702 CHINA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 703 CHINA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 704 CHINA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 705 JAPAN MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 706 JAPAN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 707 JAPAN ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 708 JAPAN NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 709 JAPAN TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 710 JAPAN OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 711 JAPAN NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 712 JAPAN ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 713 JAPAN ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 714 JAPAN ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 715 JAPAN OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 716 JAPAN PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 717 JAPAN ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 718 JAPAN CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 719 JAPAN SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 720 JAPAN ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 721 JAPAN NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 722 JAPAN BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 723 JAPAN BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 724 JAPAN CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 725 JAPAN ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 726 JAPAN NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 727 JAPAN DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 728 JAPAN MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 729 JAPAN MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 730 JAPAN MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 731 JAPAN MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 732 JAPAN MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 733 INDIA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 734 INDIA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 735 INDIA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 736 INDIA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 737 INDIA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 738 INDIA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 739 INDIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 740 INDIA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 741 INDIA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 742 INDIA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 743 INDIA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 744 INDIA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 745 INDIA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 746 INDIA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 747 INDIA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 748 INDIA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 749 INDIA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 750 INDIA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 751 INDIA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 752 INDIA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 753 INDIA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 754 INDIA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 755 INDIA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 756 INDIA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 757 INDIA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 758 INDIA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 759 INDIA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 760 INDIA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 761 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 762 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 763 SOUTH KOREA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 764 SOUTH KOREA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 765 SOUTH KOREA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 766 SOUTH KOREA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 767 SOUTH KOREA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 768 SOUTH KOREA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 769 SOUTH KOREA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 770 SOUTH KOREA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 771 SOUTH KOREA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 772 SOUTH KOREA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 773 SOUTH KOREA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 774 SOUTH KOREA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 775 SOUTH KOREA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 776 SOUTH KOREA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 777 SOUTH KOREA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 778 SOUTH KOREA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 779 SOUTH KOREA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 780 SOUTH KOREA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 781 SOUTH KOREA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 782 SOUTH KOREA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 783 SOUTH KOREA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 784 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 785 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 786 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 787 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 788 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 789 AUSTRALIA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 790 AUSTRALIA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 791 AUSTRALIA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 792 AUSTRALIA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 793 AUSTRALIA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 794 AUSTRALIA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 795 AUSTRALIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 796 AUSTRALIA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 797 AUSTRALIA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 798 AUSTRALIA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 799 AUSTRALIA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 800 AUSTRALIA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 801 AUSTRALIA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 802 AUSTRALIA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 803 AUSTRALIA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 804 AUSTRALIA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 805 AUSTRALIA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 806 AUSTRALIA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 807 AUSTRALIA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 808 AUSTRALIA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 809 AUSTRALIA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 810 AUSTRALIA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 811 AUSTRALIA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 812 AUSTRALIA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 813 AUSTRALIA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 814 AUSTRALIA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 815 AUSTRALIA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 816 AUSTRALIA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 817 SINGAPORE MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 818 SINGAPORE MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 819 SINGAPORE ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 820 SINGAPORE NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 821 SINGAPORE TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 822 SINGAPORE OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 823 SINGAPORE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 824 SINGAPORE ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 825 SINGAPORE ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 826 SINGAPORE ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 827 SINGAPORE OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 828 SINGAPORE PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 829 SINGAPORE ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 830 SINGAPORE CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 831 SINGAPORE SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 832 SINGAPORE ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 833 SINGAPORE NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 834 SINGAPORE BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 835 SINGAPORE BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 836 SINGAPORE CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 837 SINGAPORE ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 838 SINGAPORE NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 839 SINGAPORE DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 840 SINGAPORE MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 841 SINGAPORE MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 842 SINGAPORE MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 843 SINGAPORE MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 844 SINGAPORE MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 845 INDONESIA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 846 INDONESIA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 847 INDONESIA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 848 INDONESIA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 849 INDONESIA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 850 INDONESIA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 851 INDONESIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 852 INDONESIA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 853 INDONESIA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 854 INDONESIA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 855 INDONESIA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 856 INDONESIA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 857 INDONESIA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 858 INDONESIA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 859 INDONESIA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 860 INDONESIA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 861 INDONESIA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 862 INDONESIA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 863 INDONESIA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 864 INDONESIA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 865 INDONESIA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 866 INDONESIA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 867 INDONESIA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 868 INDONESIA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 869 INDONESIA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 870 INDONESIA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 871 INDONESIA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 872 INDONESIA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 873 THAILAND MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 874 THAILAND MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 875 THAILAND ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 876 THAILAND NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 877 THAILAND TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 878 THAILAND OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 879 THAILAND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 880 THAILAND ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 881 THAILAND ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 882 THAILAND ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 883 THAILAND OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 884 THAILAND PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 885 THAILAND ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 886 THAILAND CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 887 THAILAND SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 888 THAILAND ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 889 THAILAND NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 890 THAILAND BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 891 THAILAND BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 892 THAILAND CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 893 THAILAND ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 894 THAILAND NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 895 THAILAND DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 896 THAILAND MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 897 THAILAND MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 898 THAILAND MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 899 THAILAND MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 900 THAILAND MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 901 MALAYSIA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 902 MALAYSIA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 903 MALAYSIA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 904 MALAYSIA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 905 MALAYSIA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 906 MALAYSIA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 907 MALAYSIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 908 MALAYSIA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 909 MALAYSIA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 910 MALAYSIA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 911 MALAYSIA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 912 MALAYSIA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 913 MALAYSIA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 914 MALAYSIA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 915 MALAYSIA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 916 MALAYSIA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 917 MALAYSIA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 918 MALAYSIA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 919 MALAYSIA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 920 MALAYSIA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 921 MALAYSIA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 922 MALAYSIA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 923 MALAYSIA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 924 MALAYSIA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 925 MALAYSIA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 926 MALAYSIA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 927 MALAYSIA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 928 MALAYSIA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 929 PHILIPPINES MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 930 PHILIPPINES MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 931 PHILIPPINES ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 932 PHILIPPINES NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 933 PHILIPPINES TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 934 PHILIPPINES OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 935 PHILIPPINES NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 936 PHILIPPINES ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 937 PHILIPPINES ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 938 PHILIPPINES ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 939 PHILIPPINES OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 940 PHILIPPINES PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 941 PHILIPPINES ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 942 PHILIPPINES CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 943 PHILIPPINES SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 944 PHILIPPINES ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 945 PHILIPPINES NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 946 PHILIPPINES BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 947 PHILIPPINES BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 948 PHILIPPINES CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 949 PHILIPPINES ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 950 PHILIPPINES NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 951 PHILIPPINES DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 952 PHILIPPINES MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 953 PHILIPPINES MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 954 PHILIPPINES MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 955 PHILIPPINES MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 956 PHILIPPINES MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 957 VIETNAM MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 958 VIETNAM MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 959 VIETNAM ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 960 VIETNAM NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 961 VIETNAM TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 962 VIETNAM OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 963 VIETNAM NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 964 VIETNAM ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 965 VIETNAM ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 966 VIETNAM ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 967 VIETNAM OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 968 VIETNAM PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 969 VIETNAM ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 970 VIETNAM CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 971 VIETNAM SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 972 VIETNAM ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 973 VIETNAM NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 974 VIETNAM BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 975 VIETNAM BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 976 VIETNAM CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 977 VIETNAM ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 978 VIETNAM NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 979 VIETNAM DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 980 VIETNAM MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 981 VIETNAM MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 982 VIETNAM MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 983 VIETNAM MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 984 VIETNAM MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 985 REST OF ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 986 SOUTH AMERICA MIGRAINE TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 987 SOUTH AMERICA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 988 SOUTH AMERICA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 989 SOUTH AMERICA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 990 SOUTH AMERICA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 991 SOUTH AMERICA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 992 SOUTH AMERICA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 993 SOUTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 994 SOUTH AMERICA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 995 SOUTH AMERICA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 996 SOUTH AMERICA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 997 SOUTH AMERICA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 998 SOUTH AMERICA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 999 SOUTH AMERICA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1000 SOUTH AMERICA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1001 SOUTH AMERICA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1002 SOUTH AMERICA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1003 SOUTH AMERICA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1004 SOUTH AMERICA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1005 SOUTH AMERICA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1006 SOUTH AMERICA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1007 SOUTH AMERICA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1008 SOUTH AMERICA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1009 SOUTH AMERICA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1010 SOUTH AMERICA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 1011 SOUTH AMERICA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 1012 SOUTH AMERICA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 1013 SOUTH AMERICA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 1014 SOUTH AMERICA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 1015 BRAZIL MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 1016 BRAZIL MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1017 BRAZIL ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1018 BRAZIL NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1019 BRAZIL TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 1020 BRAZIL OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1021 BRAZIL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1022 BRAZIL ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1023 BRAZIL ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1024 BRAZIL ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1025 BRAZIL OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1026 BRAZIL PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1027 BRAZIL ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1028 BRAZIL CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD)

TABLE 1029 BRAZIL SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1030 BRAZIL ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1031 BRAZIL NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1032 BRAZIL BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1033 BRAZIL BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1034 BRAZIL CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1035 BRAZIL ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1036 BRAZIL NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1037 SOUTH AMERICA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1038 BRAZIL MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 1039 BRAZIL MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 1040 BRAZIL MIGRAINE TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 1041 BRAZIL MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 1042 BRAZIL MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 1043 ARGENTINA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 1044 ARGENTINA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1045 ARGENTINA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1046 ARGENTINA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1047 ARGENTINA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 1048 ARGENTINA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1049 ARGENTINA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1050 ARGENTINA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1051 ARGENTINA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1052 ARGENTINA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1053 ARGENTINA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1054 ARGENTINA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1055 ARGENTINA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1056 ARGENTINA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1057 ARGENTINA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1058 ARGENTINA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1059 ARGENTINA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1060 ARGENTINA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1061 ARGENTINA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1062 ARGENTINA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1063 ARGENTINA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1064 ARGENTINA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1065 ARGENTINA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1066 ARGENTINA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 1067 ARGENTINA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 1068 ARGENTINA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 1069 ARGENTINA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 1070 ARGENTINA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 1071 PERU MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 1072 PERU MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1073 PERU ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1074 PERU NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1075 PERU TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 1076 PERU OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1077 PERU NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1078 PERU ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1079 PERU ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1080 PERU ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1081 PERU OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1082 PERU PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1083 PERU ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1084 PERU CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1085 PERU SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1086 PERU ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1087 PERU NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1088 PERU BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1089 PERU BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1090 PERU CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1091 PERU ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1092 PERU NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1093 PERU DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1094 PERU MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 1095 PERU MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 1096 PERU MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 1097 PERU MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 1098 PERU MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 1099 REST OF SOUTH AMERICA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 1100 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 1101 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 1102 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1103 MIDDLE EAST & AFRICA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1104 MIDDLE EAST & AFRICA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1105 MIDDLE EAST & AFRICA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 1106 MIDDLE EAST & AFRICA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1107 MIDDLE EAST & AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1108 MIDDLE EAST & AFRICA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1109 MIDDLE EAST & AFRICA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1110 MIDDLE EAST & AFRICA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1111 MIDDLE EAST & AFRICA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1112 MIDDLE EAST & AFRICA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1113 MIDDLE EAST & AFRICA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1114 MIDDLE EAST & AFRICA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1115 MIDDLE EAST & AFRICA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1116 MIDDLE EAST & AFRICA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1117 MIDDLE EAST & AFRICA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1118 MIDDLE EAST & AFRICA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1119 MIDDLE EAST & AFRICA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1120 MIDDLE EAST & AFRICA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1121 MIDDLE EAST & AFRICA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1122 MIDDLE EAST & AFRICA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1123 MIDDLE EAST & AFRICA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1124 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 1125 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 1126 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 1127 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 1128 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 1129 SAUDI ARABIA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 1130 SAUDI ARABIA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1131 SAUDI ARABIA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1132 SAUDI ARABIA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1133 SAUDI ARABIA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 1134 SAUDI ARABIA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1135 SAUDI ARABIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1136 SAUDI ARABIA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1137 SAUDI ARABIA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1138 SAUDI ARABIA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1139 SAUDI ARABIA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1140 SAUDI ARABIA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1141 SAUDI ARABIA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1142 SAUDI ARABIA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1143 SAUDI ARABIA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1144 SAUDI ARABIA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1145 SAUDI ARABIA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1146 SAUDI ARABIA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1147 SAUDI ARABIA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1148 SAUDI ARABIA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1149 SAUDI ARABIA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1150 SAUDI ARABIA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1151 SAUDI ARABIA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1152 SAUDI ARABIA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 1153 SAUDI ARABIA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 1154 SAUDI ARABIA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 1155 SAUDI ARABIA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 1156 SAUDI ARABIA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 1157 SOUTH AFRICA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 1158 SOUTH AFRICA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1159 SOUTH AFRICA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1160 SOUTH AFRICA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1161 SOUTH AFRICA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 1162 SOUTH AFRICA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1163 SOUTH AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1164 SOUTH AFRICA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1165 SOUTH AFRICA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1166 SOUTH AFRICA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1167 SOUTH AFRICA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1168 SOUTH AFRICA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1169 SOUTH AFRICA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1170 SOUTH AFRICA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1171 SOUTH AFRICA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1172 SOUTH AFRICA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1173 SOUTH AFRICA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1174 SOUTH AFRICA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1175 SOUTH AFRICA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1176 SOUTH AFRICA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLIONX`)

TABLE 1177 SOUTH AFRICA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1178 SOUTH AFRICA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1179 SOUTH AFRICA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1180 SOUTH AFRICA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 1181 SOUTH AFRICA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 1182 SOUTH AFRICA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 1183 SOUTH AFRICA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 1184 SOUTH AFRICA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 1185 UAE MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 1186 UAE MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1187 UAE ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1188 UAE NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1189 UAE TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 1190 UAE OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1191 UAENONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1192 UAE ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1193 UAE ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1194 UAE ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1195 UAE OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1196 UAE PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1197 UAE ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1198 UAE CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1199 UAE SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1200 UAE ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1201 UAE NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1202 UAE BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1203 UAE BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1204 UAE CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1205 UAE ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1206 UAE NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1207 UAE DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1208 UAE MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 1209 UAE MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 1210 UAE MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 1211 UAE MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 1212 UAE MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 1213 ISRAEL MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 1214 ISRAEL MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1215 ISRAEL ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1216 ISRAEL NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1217 ISRAEL TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 1218 ISRAEL OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1219 ISRAELNONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1220 ISRAEL ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1221 ISRAEL ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1222 ISRAEL ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1223 ISRAEL OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1224 ISRAEL PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1225 ISRAEL ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1226 ISRAEL CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1227 ISRAEL SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1228 ISRAEL ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1229 ISRAEL NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1230 ISRAEL BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1231 ISRAEL BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1232 ISRAEL CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1233 ISRAEL ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1234 ISRAEL NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1235 ISRAEL DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1236 ISRAEL MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 1237 ISRAEL MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 1238 ISRAEL MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 1239 ISRAEL MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 1240 ISRAEL MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 1241 KUWAIT MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 1242 KUWAIT MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1243 KUWAIT ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1244 KUWAIT NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1245 KUWAIT TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 1246 KUWAIT OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1247 KUWAITNONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1248 KUWAIT ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1249 KUWAIT ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1250 KUWAIT ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1251 KUWAIT OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1252 KUWAIT PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1253 KUWAIT ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1254 KUWAIT CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1255 KUWAIT SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1256 KUWAIT ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1257 KUWAIT NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1258 KUWAIT BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1259 KUWAIT BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1260 KUWAIT CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1261 KUWAIT ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1262 KUWAIT NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1263 KUWAIT DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1264 KUWAIT MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 1265 KUWAIT MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 1266 KUWAIT MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 1267 KUWAIT MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 1268 KUWAIT MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 1269 EGYPT MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 1270 EGYPT MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1271 EGYPT ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1272 EGYPT NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1273 EGYPT TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 1274 EGYPT OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1275 EGYPTNONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1276 EGYPT ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1277 EGYPT ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1278 EGYPT ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1279 EGYPT OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1280 EGYPT PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1281 EGYPT ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1282 EGYPT CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1283 EGYPT SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1284 EGYPT ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1285 EGYPT NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1286 EGYPT BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1287 EGYPT BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1288 EGYPT CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1289 EGYPT ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1290 EGYPT NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1291 EGYPT DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 1292 EGYPT MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 1293 EGYPT MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 1294 EGYPT MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 1295 EGYPT MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 1296 EGYPT MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 1297 REST OF MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 1298 SUBSIDIARIES OF JANSSEN GLOBAL SERVICES, LLC

 

Lista de figuras

LIST OF FIGURES 

FIGURE 1 GLOBAL MIGRAINE TREATMENT MARKET: SEGMENTATION

FIGURE 2 GLOBAL MIGRAINE TREATMENT MARKET : DATA TRIANGULATION

FIGURE 3 GLOBAL MIGRAINE TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL MIGRAINE TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL MIGRAINE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL MIGRAINE TREATMENT MARKET: MULTIVARIATE MODELLING

FIGURE 7 GLOBAL MIGRAINE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 GLOBAL MIGRAINE TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 GLOBAL MIGRAINE TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL MIGRAINE TREATMENT MARKET

FIGURE 11 RESULT OF PREVALENCE OF MIGRAINE FROM ONE YEAR STUDY

FIGURE 12 GLOBAL MIGRAINE TREATMENT MARKET: SEGMENTATION

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL MIGRAINE TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027

FIGURE 14 INCREASING PREVALNCE OF MIGRAINE AND DEVELOPMENT OF NOVEL DRUGS IS DRIVING THE GLOBAL MIGRAINE TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027

FIGURE 15 EPISODIC IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL MIGRAINE TREATMENT MARKET IN 2020 & 2027

FIGURE 16 ASIA-PACIFIC IS THE FASTEST GROWING MARKET IN GLOBAL MIGRAINE TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027

FIGURE 17 GLOBAL PREVALENCE OF MIGRAINE TREATMENT (2018)

FIGURE 18 GLOBAL MIGRAINE TREATMENT MARKET: BY TYPES OF MIGRAINE, 2019

FIGURE 19 GLOBAL MIGRAINE TREATMENT MARKET: BY TYPES OF MIGRAINE, 2019-2027 (USD MILLION)

FIGURE 20 GLOBAL MIGRAINE TREATMENT MARKET: BY TYPES OF MIGRAINE, CAGR (2020-2027)

FIGURE 21 GLOBAL MIGRAINE TREATMENT MARKET: BY TYPES OF MIGRAINE, LIFELINE CURVE

FIGURE 22 GLOBAL MIGRAINE TREATMENT MARKET: BY TREATMENT, 2019

FIGURE 23 GLOBAL MIGRAINE TREATMENT MARKET: BY TREATMENT, 2019-2027 (USD MILLION)

FIGURE 24 GLOBAL MIGRAINE TREATMENT MARKET: BY TREATMENT, CAGR (2020-2027)

FIGURE 25 GLOBAL MIGRAINE TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 26 GLOBAL MIGRAINE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2019

FIGURE 27 GLOBAL MIGRAINE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)

FIGURE 28 GLOBAL MIGRAINE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027)

FIGURE 29 GLOBAL MIGRAINE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 30 GLOBAL MIGRAINE TREATMENT MARKET: BY PRODUCT TYPE, 2019

FIGURE 31 GLOBAL MIGRAINE TREATMENT MARKET: BY PRODUCT TYPE, 2019-2027 (USD MILLION)

FIGURE 32 GLOBAL MIGRAINE TREATMENT MARKET: BY PRODUCT TYPE, CAGR (2020-2027)

FIGURE 33 GLOBAL MIGRAINE TREATMENT MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 34 GLOBAL MIGRAINE TREATMENT MARKET: BY TYPE, 2019

FIGURE 35 GLOBAL MIGRAINE TREATMENT MARKET: BY TYPE, 2019-2027 (USD MILLION)

FIGURE 36 GLOBAL MIGRAINE TREATMENT MARKET: BY TYPE, CAGR (2020-2027)

FIGURE 37 GLOBAL MIGRAINE TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 38 GLOBAL MIGRAINE TREATMENT MARKET: BY END USER, 2019

FIGURE 39 GLOBAL MIGRAINE TREATMENT MARKET: BY END USER, 2019-2027 (USD MILLION)

FIGURE 40 GLOBAL MIGRAINE TREATMENT MARKET: BY END USER, CAGR (2020-2027)

FIGURE 41 GLOBAL MIGRAINE TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 42 GLOBAL MIGRAINE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019

FIGURE 43 GLOBAL MIGRAINE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

FIGURE 44 GLOBAL MIGRAINE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)

FIGURE 45 GLOBAL MIGRAINE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 46 GLOBAL MIGRAINE TREATMENT MARKET: SNAPSHOT (2019)

FIGURE 47 GLOBAL MIGRAINE TREATMENT MARKET: BY REGION (2019)

FIGURE 48 GLOBAL MIGRAINE TREATMENT MARKET: BY REGION (2020 & 2027)

FIGURE 49 GLOBAL MIGRAINE TREATMENT MARKET: BY REGION (2019 & 2027)

FIGURE 50 GLOBAL MIGRAINE TREATMENT MARKET: BY TYPES OF MIGRAINE (2020-2027)

FIGURE 51 NORTH AMERICA MIGRAINE TREATMENT MARKET: SNAPSHOT (2019)

FIGURE 52 NORTH AMERICA MIGRAINE TREATMENT MARKET: BY COUNTRY (2019)

FIGURE 53 NORTH AMERICA MIGRAINE TREATMENT MARKET: BY COUNTRY (2020 & 2027)

FIGURE 54 NORTH AMERICA MIGRAINE TREATMENT MARKET: BY COUNTRY (2019 & 2027)

FIGURE 55 NORTH AMERICA MIGRAINE TREATMENT MARKET: BY TYPES OF MIGRAINE (2020-2027)

FIGURE 56 EUROPE MIGRAINE TREATMENT MARKET: SNAPSHOT (2019)

FIGURE 57 EUROPE MIGRAINE TREATMENT MARKET: BY COUNTRY (2019)

FIGURE 58 EUROPE MIGRAINE TREATMENT MARKET: BY COUNTRY (2020 & 2027)

FIGURE 59 EUROPE MIGRAINE TREATMENT MARKET: BY COUNTRY (2019 & 2027)

FIGURE 60 EUROPE MIGRAINE TREATMENT MARKET: BY TYPES OF MIGRAINE (2020-2027)

FIGURE 61 ASIA-PACIFIC MIGRAINE TREATMENT MARKET: SNAPSHOT (2019)

FIGURE 62 ASIA-PACIFIC MIGRAINE TREATMENT MARKET: BY COUNTRY (2019)

FIGURE 63 ASIA-PACIFIC MIGRAINE TREATMENT MARKET: BY COUNTRY (2020 & 2027)

FIGURE 64 ASIA-PACIFIC MIGRAINE TREATMENT MARKET: BY COUNTRY (2019 & 2027)

FIGURE 65 ASIA-PACIFIC MIGRAINE TREATMENT MARKET: BY TYPES OF MIGRAINE (2020-2027)

FIGURE 66 SOUTH AMERICA MIGRAINE TREATMENT MARKET: SNAPSHOT (2019)

FIGURE 67 SOUTH AMERICA MIGRAINE TREATMENT MARKET: BY COUNTRY (2019)

FIGURE 68 SOUTH AMERICA MIGRAINE TREATMENT MARKET: BY COUNTRY (2020 & 2027)

FIGURE 69 SOUTH AMERICA MIGRAINE TREATMENT MARKET: BY COUNTRY (2019 & 2027)

FIGURE 70 SOUTH AMERICA MIGRAINE TREATMENT MARKET: BY TREATMENT (2020-2027)

FIGURE 71 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET: SNAPSHOT (2019)

FIGURE 72 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET: BY COUNTRY (2019)

FIGURE 73 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET: BY COUNTRY (2020 & 2027)

FIGURE 74 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET: BY COUNTRY (2019 & 2027)

FIGURE 75 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET: BY TYPES OF MIGRAINE (2020-2027)

FIGURE 76 GLOBAL MIGRAINE TREATMENT MARKET: COMPANY SHARE 2019 (%)

FIGURE 77 NORTH AMERICA MIGRAINE TREATMENT MARKET: COMPANY SHARE 2019 (%)

FIGURE 78 EUROPE MIGRAINE TREATMENT MARKET: COMPANY SHARE 2019 (%)

FIGURE 79 ASIA-PACIFIC MIGRAINE TREATMENT MARKET: COMPANY SHARE 2019 (%)

 

Ver información detallada Right Arrow

Metodología de investigación

La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.

La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.

Personalización disponible

Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados ​​en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.

Preguntas frecuentes

The Migraine Treatment Market size will be worth USD 4.67 billion by 2029
The Growth Rate of Migraine Treatment Market is 8.80% by 2029
Growing awareness regarding migraine and increase in migraine prevalence and diagnosis is the Growth Drivers of the Migraine Treatment Market
The major companies in the Migraine Treatment Market report are Pfizer Inc. (U.S), Eli Lilly and Company (U.S), Amgen Inc. (U.S), GlaxoSmithKline plc. (U.K), Novartis AG (Switzerland), Bayer AG (Germany), Allergan (Ireland), Abbott (U.S), Allodynic Therapeutics, LLC (U.S), AOBiome (U.S), AstraZeneca (U.K), Aurobindo Pharma USA (U.S), Bausch Health Companies Inc. (Canada), Biohaven Pharmaceuticals (U.S), Boehringer Ingelheim International GmbH (Germany), Catalent, Inc (U.S), Dr. Reddy’s Laboratories Ltd. (India), Impel Pharmaceuticals Inc. (U.S), H. Lundbeck A/S (Denmark), Merck & Co., Inc (U.S) etc
Type, treatment, route of administration, product, distribution channel and end-user are the factors on which the Migraine Treatment Market research is based

Explorar páginas relacionadas

Banner